Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
GFRAL is a receptor belonging to the GDNF receptor family, specific to GDF15. Upon binding, it forms a complex with the RET tyrosine kinase, modulating appetite and energy homeostasis. Primarily expressed in the area postrema and nucleus tractus solitarius of the brainstem, GFRAL is a promising therapeutic target for obesity and cachexia. Blocking the GDF15-GFRAL-RET pathway shows promise in reversing cachexia symptoms.
Agonists for obesity treatment, antagonists for cachexia therapy
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Glial cell-derived neurotrophic factor family receptor alpha-like (GFRAL).